A post hoc analysis of OPERA I and II and ORATORIO revealed a nonsignificant trend toward an association of higher median B-cell levels with higher rates of 24-week confirmed disability progression during the 96-week double-blind period and open-label extension [ 111 ].
← all excerpts
The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function.
1
—
—